Type of information: Company acquisition
Acquired company: Rigontec (Germany)
Acquiring company: Merck&Co (USA - NJ)
Amount: up to $ 464 million
- • On September 6, 2017, Merck&Co and Rigontec announced that Merck&Co will acquire Rigontec. Under the terms of the agreement, Merck&Co, through a subsidiary, will make an upfront cash payment of €115 million to Rigontec’s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck&Co may make additional contingent payments of up to €349 million. The transaction is subject to certain closing conditions.
- Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Its lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.
Related: Cancer - Oncology